Resultado de búsqueda
19 de jun. de 2020 · Themis is now a wholly-owned subsidiary of Merck. An initial focus of this agreement is acceleration of the development of a measles vector-based SARS-CoV-2 vaccine candidate. This candidate is currently in pre-clinical development, and clinical studies are planned to start later in 2020.
26 de may. de 2020 · Themis is developing immunomodulation therapies for infectious diseases and cancer. Through advanced understanding of immune system mechanisms, the company has built a sophisticated and versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches.
Merck has agreed to acquire Themis Bioscience, an Austrian pharma company, which is currently engaged in developing a vaccine for COVID-19.
19 de nov. de 2014 · The Vienna-based biotech company Themis Bioscience GmbH (‘Themis’) today received final results of a phase 1 clinical study of its prophylactic Chikungunya fever vaccine.
Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases.
26 de may. de 2020 · Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists...
26 de feb. de 2019 · After turning up positive phase 2 data late last year, Themis Bioscience’ chikungunya vaccine candidate has picked up an FDA “fast track” designation that comes with closer assistance from the...
